Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study)

BackgroundIn order to compare the effectiveness of different antipsychotic drugs in the treatment of schizophrenia it is very important to evaluate subjective response and compliance in patient cohorts treated according to routine clinical practice.MethodOutpatients with schizophrenia entered this prospective, naturalistic study when they received a new prescription for an antipsychotic drug. Treatment assignment was based on purely clinical criteria, as the study did not include any experimental intervention. Patients treated with olanzapine, risperidone or haloperidol were included in the analysis. Subjective response was measured using the 10-item version of the Drug Attitude Inventory (DAI-10), and treatment compliance was measured using a physician-rated 4 point categorical scale.ResultsA total of 2128 patients initiated treatment (as monotherapy) with olanzapine, 417 with risperidone, and 112 with haloperidol. Olanzapine-treated patients had significantly higher DAI-10 scores and significantly better treatment compliance compared to both risperidone- and haloperidol-treated patients. Risperidone-treated patients had a significantly higher DAI-10 score compared to haloperidol-treated patients.ConclusionSubjective response and compliance were superior in olanzapine-treated patients, compared to patients treated with risperidone and haloperidol, in routine clinical practice. Differences in subjective response were explained largely, but not completely, by differences in incidence of EPS.

• Publication year

  2001

• Venue

  BMC Psychiatry

• Publication date

  2001-12-28

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1186/1471-244X-1-7PMID 11835695PMCID 65550
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life.

  2000cited by this paper
• Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.

  2000cited by this paper
• Doses of Olanzapine, Risperidone, and Haloperidol Used in Clinical Practice: Results of a Prospective Pharmacoepidemiologic Study

  2000cited by this paper
• Antipsychotic treatment and changes in health related quality of life in patients with schizophrenia using EQ-5D

  2000cited by this paper
• The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.

  2000cited by this paper
• Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study.

  2000cited by this paper
• Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors.

  2000cited by this paper
• Quality of life in schizophrenia: insight and subjective response to neuroleptics.

  1998cited by this paper
• Substance abuse in schizophrenia: a review.

  1998cited by this paper
• Phase-IV Multicentre Clinical Study of Risperidone in the Treatment of Outpatients with Schizophrenia

  1998cited by this paper
• Subjective response to neuroleptics in schizophrenia

  1997influential reference
• Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse.

  1997cited by this paper
• Psychological Predictors of Insight and Compliance in Psychotic Patients

  1996cited by this paper
• Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome

  1996cited by this paper
• A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables

  1995cited by this paper
• Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life

  1995cited by this paper
• Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life.

  1995cited by this paper
• Rating of medication influences (ROMI) scale in schizophrenia.

  1994cited by this paper
• Subjective response to neuroleptics in schizophrenia.

  1993cited by this paper
• Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures

  1992influential reference
• Clinical Management of Clozapine Patients in Relation to Efficacy and Side-Effects

  1992cited by this paper
• Neuroleptic depression in schizophrenia.

  1991cited by this paper
• Neuroleptic dysphoria.

  1991cited by this paper
• Neuroleptic dysphoria in animals.

  1991cited by this paper
• Neuroleptic-induced anhedonia: Recent studies

  1989cited by this paper
• Drug therapy in schizophrenia — prediction of outcome A. George Awad and Thomas P. Hogan Department of Psychiatry, University of Toronto, The Wellesley Hospital, 160 Wellesley St. E, Toronto M4Y 1J3, Canada

  1988cited by this paper
• Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder.

  1988cited by this paper
• Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder.

  1988cited by this paper
• The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients

  1987cited by this paper
• Utility of the health belief model in examining medication compliance among psychiatric outpatients.

  1987cited by this paper
• Early treatment events and prediction of response to neuroleptics in schizophrenia.

  1985cited by this paper
• Response to antipsychotic medication: the doctor's and the consumer's view.

  1984cited by this paper
• A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity

  1983influential reference
• Subjective response to antipsychotic drugs.

  1981cited by this paper
• Haloperidol-induced dysphoria in patients with Tourette syndrome.

  1979cited by this paper
• Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride.

  1979cited by this paper
• Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis.

  1979cited by this paper
• A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia

  1978cited by this paper
• Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point.

  1978cited by this paper
• The importance of body experience for psychiatry.

  1977cited by this paper
• Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance.

  1976cited by this paper
• Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance.

  1976cited by this paper
• Akinesia: A Poorly Recognized Drug-Induced Extrapyramidal Behavioral Disorder

  1975cited by this paper
• Very high dosage vs standard dosage fluphenazine in schizophrenia. A double-blind study of nonchronic treatment-refractory patients.

  1975cited by this paper
• Kinetics and dynamics of response to haloperidol in acute schizophrenia--A longitudinal study of the therapeutic process.

  1973cited by this paper
• Veränderungen der subjektiven Befindlichkeit psychotischer Patienten unter neuroleptischer Therapie

  1972cited by this paper
• Clinical handbook of psychopharmacology

  1970cited by this paper

• Olanzapina, 26 años: situación actual, conocimientos, actitudes y prácticas de uso entre los psiquiatras españoles

  2023cites this paper
• Administration of High-Risk Medication: A Hospital Based Prospective Study

  2022cites this paper
• Assessment of the extrapyramidal side effects among psychosis patients consuming antipsychotic medication with a view to develop an information leaflet on early recognition and management of extrapyramidal side effects in SS selected hospital at Raipur

  2021cites this paper
• Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology

  2019cites this paper
• Subjective response to antipsychotics in bipolar disorders: A review of a neglected area

  2019cites this paper
• A Longitudinal Comparison of Bipolar Disorder and Schizophrenia From India

  2019cites this paper
• NDT_A_209284 2559..2569

  2019cites this paper
• A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future

  2019cites this paper
• Attitudes to Medication-Treatment Among Patients and Caregivers: A Longitudinal Comparison of Bipolar Disorder and Schizophrenia From India.

  2019cites this paper
• Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later

  2018cites this paper
• Tardive dyskinesia risk with first‐ and second‐generation antipsychotics in comparative randomized controlled trials: a meta‐analysis

  2018cites this paper
• Classification of psychopathology: conceptual and historical background

  2018cites this paper
• Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands

  2017cites this paper
• Nuspojave antipsihotika tijekom liječenja shizofrenije

  2017cites this paper
• Predictors of negative symptoms in the chronic phase of schizophrenia: A cross-sectional study.

  2017cites this paper
• Studying medication adherence in patients with schizophrenia: focus on antipsychotic-related factors

  2016cites this paper
• Schizophrenia in the Netherlands: Continuity of Care with Better Quality of Care for Less Medical Costs

  2016cites this paper
• Obesity-related metabolic disturbances and quality of life in subjects diagnosed with schizophrenia treated with atypical neuroleptics

  2016cites this paper
• Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders

  2015cites this paper
• RELATIONSHIP BETWEEN INSIGHTS INTO THE DISEASE WITH COMPLIANCE IN SCHIZOPHRENIC PATIENTS

  2014cites this paper
• Poor Adherence to Antipsychotic Medication in People with Schizophrenia: Diffusion, Consequences and Contributing Factors

  2014cites this paper
• Attitudes Towards Antipsychotics Among Patients with Schizophrenia on First- or Second-Generation Medications

  2014influential citation
• Pharmacological Strategies to Enhance Adherence in Schizophrenia

  2014cites this paper
• Serotonergic organization of the central nervous system.

  2012cites this paper
• Short-term clinical stability and lack of insight are associated with a negative attitude towards antipsychotic treatment at discharge in patients with schizophrenia and bipolar disorder

  2012cites this paper
• Adesão ao tratamento medicamentoso em pacientes do espectro esquizofrênico: uma revisão sistemática da literatura Adherence to drug treatment among schizophrenic spectrum patients: a systematic review of the literature

  2012cites this paper
• Adesão ao tratamento medicamentoso em pacientes do espectro esquizofrênico: uma revisão sistemática da literatura

  2012cites this paper
• Connecting the dots : new perspectives on stress and psychosis

  2012cites this paper
• Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study.

  2011cites this paper
• Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology

  2011cites this paper
• Schizophrenia-related outpatient treatment of Medicaid-financed patients after hospital discharge.

  2011cites this paper
• The structure of FANCL, the catalytic subunit of the Fanconi Anemia core complex

  2010cites this paper
• Telephone-based nursing strategy to improve adherence to antipsychotic treatment in schizophrenia: A controlled trial

  2010cites this paper
• Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia

  2010cites this paper
• Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.

  2010cites this paper
• TCD MONITORING OF CEREBRAL BLOOD FLOW

  2010cites this paper
• Engineering of glycosylation in yeast and other fungi: current state and perspectives

  2010cites this paper
• FANCM regulates DNA chain elongation and is stabilized by S‐phase checkpoint signalling

  2010cites this paper
• Factors Affecting Treatment Discontinuation and Treatment Outcome in Patients with Schizophrenia in Korea: 10-Year Follow-Up Study

  2010cites this paper
• Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report

  2010cites this paper
• DNA Polymerase POLN Participates in Cross-Link Repair and Homologous Recombination

  2009cites this paper
• FANCM connects the genome instability disorders Bloom's Syndrome and Fanconi Anemia.

  2009cites this paper
• Postmarketing cohort study to assess the safety profile of oral dexketoprofen trometamol for mild to moderate acute pain treatment in primary care.

  2009cites this paper
• XPF-ERCC1 Participates in the Fanconi Anemia Pathway of Cross-Link Repair

  2009cites this paper
• Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia.

  2009cites this paper
• The ubiquitin landscape at DNA double-strand breaks

  2009cites this paper
• Switching to Aripiprazole in Outpatients with Schizophrenia Experiencing Insufficient Efficacy and/or Safety/Tolerability Issues with Risperidone: A Randomized, Multicentre, Open-label Study

  2009cites this paper
• Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

  2009cites this paper
• Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia

  2008cites this paper
• Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia.

  2008cites this paper
• Subjective and psychopathological response in patients under different antipsychotic treatments: are there differences in real clinical practice?

  2008cites this paper
• Limitations of current therapies: why do patients switch therapies?

  2008cites this paper
• Large-Scale Production of Human Adipose Tissue from Stem Cells: A New Tool for Regenerative Medicine and Tissue Banking

  2008cites this paper
• Well-being and co-morbidity in recent onset schizophrenia

  2008cites this paper
• Auswirkungen der Befragungsmethode auf die Angabe von Wirkungen und Nebenwirkungen von Antipsychotika

  2008cites this paper
• Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.

  2008cites this paper
• Well-being and co-morbidity in recent onset schizophrenia

  2008cites this paper
• Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.

  2008cites this paper
• Association between perceived racism and medication adherence in patients of Caribbean origin with psychosis.

  2008cites this paper
• [Impact of the interview technique on the statement of effects and side-effects of antipsychotic agents].

  2008cites this paper
• Anatomic variation of the 5th extensor tendon compartment and extensor digiti minimi tendon

  2007cites this paper
• Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM.

  2007cites this paper
• Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability

  2007cites this paper
• A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway.

  2007cites this paper
• The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents

  2007cites this paper
• Deubiquitination of FANCD2 Is Required for DNA Crosslink Repair

  2007cites this paper
• Human Mus81 and FANCB independently contribute to repair of DNA damage during replication

  2007cites this paper
• Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype.

  2007cites this paper
• Cost‐effectiveness of antipsychotics for outpatients with chronic schizophrenia

  2007cites this paper
• Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer

  2007cites this paper
• Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.

  2007cites this paper
• A requirement of FancL and FancD2 monoubiquitination in DNA repair

  2007cites this paper
• DNA Structure-Induced Recruitment and Activation of the Fanconi Anemia Pathway Protein FANCD2

  2007cites this paper
• TNF-alpha induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells.

  2007cites this paper
• NYÍLTMEGFIGYELÉSESVIZSGÁLATSZKIZOFRÉ-NIÁSJÁRÓBETEGEKKÖRÉBEN : HATÉKONYSÁGI ÉSBIZTONSÁGOSSÁGIADATOK 6 HÓNAPOT KÖVETÕEN . ANemzetköziSzkizofréniaJáróbeteg EgészségiKihatásvizsgálat ( The InternationalSchizo-phreniaOutpatientHealthOutcomesstudy , IC-SOHO )

  2007cites this paper
• Bilateral atresia of the submandibular duct orifices.

  2007cites this paper
• Amplification and translocation of 3q26 with overexpression of EVI1 in Fanconi anemia‐derived childhood acute myeloid leukemia with biallelic FANCD1/BRCA2 disruption

  2007cites this paper
• FAAP100 is essential for activation of the Fanconi anemia‐associated DNA damage response pathway

  2007cites this paper
• Identification, developmental expression and regulation of the Xenopus ortholog of human FANCG/XRCC9

  2007cites this paper
• Myeloid lineage‐selective growth of revertant cells in Fanconi anaemia

  2006cites this paper
• [The intercontinental schizophrenia outpatient health outcomes study (IC-SOHO): initial 6 month findings of the sample in Latin America].

  2006cites this paper
• Collaboration of Werner syndrome protein and BRCA1 in cellular responses to DNA interstrand cross-links

  2006cites this paper
• DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes.

  2006cites this paper
• Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.

  2006cites this paper
• FANCD2 associated with sporadic breast cancer risk.

  2006cites this paper
• Spectrum and significance of variants and mutations in the Fanconi anaemia group G gene in children with sporadic acute myeloid leukaemia

  2006cites this paper
• Lysine 63-Polyubiquitination Guards against Translesion Synthesis–Induced Mutations

  2006cites this paper
• Delayed diagnosis and complications of Fanconi anaemia at advanced age – a paradigm

  2006cites this paper
• Genetic analysis of chromosome pairing, recombination, and cell cycle control during first meiotic prophase in mammals.

  2006cites this paper
• [Quality of care indicators related to premature readmission and death after hospitalization for heart failure].

  2006cites this paper
• UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation.

  2006cites this paper
• Extrapyramidal side effects with atypical neuroleptics in bipolar disorder.

  2006cites this paper
• Deconstructing the molecular portrait of basal-like breast cancer.

  2006cites this paper
• Phosphorylation of FANCD2 on Two Novel Sites Is Required for Mitomycin C Resistance

  2006cites this paper
• DNA damage responses and their many interactions with the replication fork.

  2006cites this paper
• Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics.

  2006cites this paper
• RAD18‐independent ubiquitination of proliferating‐cell nuclear antigen in the avian cell line DT40

  2006cites this paper
• The relationship between patient satisfaction and treatment outcomes in schizophrenia

  2006influential citation
• Fanconi anemia.

  2006cites this paper
• Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics.

  2006cites this paper